Tisotumab vedotin
Based on 1 Customer Validation
Tisotumab vedotin is an antibody drug conjugate (ADC) targeting tissue factor (TF), formed by covalently linking a fully human monoclonal antibody (TF-011) against TF with the microtubule disruptor Monomethyll Auristatin E (MMAE) (HY-15162), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Tisotumab vedotin has immunomodulatory and anti-tumor activities, and can be used in the study of advanced or metastatic solid tumors such as cervical cancer.
For research use only. We do not sell to patients.
- Purity: 96.34%
- CAS No.: 1418731-10-8
- Molecular Weight:152000 (average)
-
Storage:
-80°C, protect from light
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
tissue factor[1].
Tisotumab vedotin induces immunogenic cell death in tumor cells expressing TF, leading to the release of endoplasmic reticulum stress markers, ATP, and high mobility histone B1 (HMGB1)[1]. Tisotumab vedotin induces anti-tumor activity through MMAE mediated cytotoxicity, Fc mediated antibody dependent cell phagocytosis (ADCP), and Fab mediated protease activated receptor 2 (PAR-2) signaling inhibition[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:HPAF-II, SCID mice[4].
-
Dosage:2 mg/kg
-
Administration:Once daily; 25 days
-
Result:Decreased the tumor volume over the 3-week window.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 1418731-10-8
-
Appearance Liquid
-
Molecular Weight 152000 (average)
-
Color Colorless to light yellow
-
SMILES
[Tisotumab vedotin]
-
Shipping
Shipping with dry ice.
-
Storage
-80°C, protect from light
Purity & Documentation
-
Data Sheet (268 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
[3]. Luu K, et al. A review of the novel tissue factor antibody-drug conjugate: Tisotumab vedotin. J Oncol Pharm Pract. 2023 Mar;29(2):441-449. [Content Brief]
[4]. Rubahamya B, et al. Clinical translation of antibody drug conjugate dosing in solid tumors from preclinical mouse data. Sci Adv. 2024 May 31;10(22):eadk1894. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz